51
|
Xing Z, Hasty KA, Smith RA. Administration of pamidronate alters bone-titanium attachment in the presence of endotoxin-coated polyethylene particles. J Biomed Mater Res B Appl Biomater 2007; 83:354-8. [PMID: 17385218 DOI: 10.1002/jbm.b.30803] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Bisphosphonates are promising in the treatment of periprosthetic osteolysis induced by particulate wear debris. The in vivo effects of pamidronate with different doses and durations of administration on bone-titanium attachment in the presence of endotoxin-coated polyethylene particles were examined in a rat model in this study. Titanium pins and endotoxin-coated polyethylene particles were introduced into rat femoral canals followed by intraperitoneal injection of pamidronate every other day. The treatment varied in the dose from 0 to 40 microg/kg and the duration of either 10 days or 6 weeks. Bilateral femurs were harvested after 6 weeks and examined by bone densitometer and MicroCT scan. Pamidronate increased the bone density of the left, unoperated femurs in a dose and duration dependent manner. Bone-titanium attachment significantly increased in all treatment groups compared to the control group. When pamidronate was administered for 10 days, the increase of bone-titanium attachment was significantly dose-dependent. However, when pamidronate was given for 6 weeks at 4 microg/kg, the bone-titanium attachment was significantly (p < 0.001) lower compared to the 10 day treatment of the same dose, although it was significantly higher than controls. Our results suggest that pamidronate effectively increase bone-titanium attachment even in the presence of endotoxin-coated polyethylene particles. However, long-term administration may reduce its efficacy.
Collapse
Affiliation(s)
- Zhiqing Xing
- Department of Orthopaedic Surgery, University of Tennessee--Campbell Clinic, Memphis, Tennessee 38163, USA.
| | | | | |
Collapse
|
52
|
Dayer R, Badoud I, Rizzoli R, Ammann P. Defective implant osseointegration under protein undernutrition: prevention by PTH or pamidronate. J Bone Miner Res 2007; 22:1526-33. [PMID: 17563238 DOI: 10.1359/jbmr.070610] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
UNLABELLED Protein deficiency is associated with impaired titanium osseointegration. We studied whether systemic treatment with PTH or pamidronate could influence the resistance to pull-out of titanium rods implanted into rats proximal tibia under normal and isocaloric low protein intake. PTH or pamidronate prevented the deleterious effects of protein undernutrition on bone microarchitecture close to the implant and on mechanical fixation. PTH even significantly improved implant osseointegration. INTRODUCTION Protein deficiency is highly prevalent among elderly patients hospitalized in orthopedic wards. Reduced protein intake impairs titanium osseointegration in rats. Whether stimulator of bone formation or inhibitor of bone resorption could improve implant osseointegration under protein deprivation is not known. We studied the effects of systemic treatment with PTH or pamidronate on the resistance to pull-out of titanium rods implanted into rats proximal tibia under normal and isocaloric low protein intake. MATERIALS AND METHODS We measured the resistance to pull-out 1-mm-diameter titanium rods implanted into the proximal tibias of 49 adult female rats receiving a normal or an isocaloric low protein diet. After 2 wk on either diet, the implants were inserted, and the rats received PTH(1-34), pamidronate or saline vehicle for 8 wk. The tibias were removed for microCT morphometry, followed by the evaluation of pull-out strength. RESULTS Pull-out strength was lower in rats fed an isocaloric low protein diet compared with rats fed a normal protein intake (-29%). PTH and pamidronate significantly increased pull-out strength in animals fed a normal or a low protein diet, the effect of PTH being of higher magnitude. The PTH- or pamidronate-mediated increase in pull-out strength was associated with significant increases of relative bone volume, bone-to-implant contact, and trabecular thickness, whereas trabecular spacing was reduced, in the vicinity of the implants. CONCLUSIONS We confirmed that isocaloric low protein intake impairs titanium implant osseointegration. PTH or pamidronate prevented the deleterious effects of protein undernutrition and even significantly improved the implant osseointegration. These results indicate that systemic administration of PTH or pamidronate could be considered for preventing uncemented arthroplasty loosening in protein undernourished patients.
Collapse
Affiliation(s)
- Romain Dayer
- Division of Bone Diseases (WHO Collaborating Center for Osteoporosis Prevention), Department of Rehabilitation and Geriatrics, University Hospitals of Geneva, Geneva, Switzerland
| | | | | | | |
Collapse
|
53
|
Jensen TB, Bechtold JE, Chen X, Søballe K. Systemic alendronate treatment improves fixation of press-fit implants: a canine study using nonloaded implants. J Orthop Res 2007; 25:772-8. [PMID: 17318896 DOI: 10.1002/jor.20272] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Bone resorption associated with local trauma occurring during insertion of joint prostheses is recognized as an early event. Being an osteoclastic inhibitor, alendronate is a potential candidate means to decrease early periprosthetic bone resorption and thereby improve implant fixation. We investigated the influence of oral alendronate treatment on early implant fixation in two implant interface settings representing sites of an implant that are in contact with surrounding bone, and other sites without intimate bone contact. One plasma-sprayed cylindrical titanium implant (6 mm diameter) was inserted into each proximal tibia of 16 dogs. On one side the implant was inserted press-fit whereas on the contralateral side, the implants were surrounded by a 2 mm concentric gap. Oral alendronate (0.5 mg/kg/day) was given 2 weeks following surgery to eight dogs. The dogs were euthanized after 10 weeks of alendronate treatment. Bone ongrowth (bone in contact with implant surface) was estimated using the linear intercept technique and shear strength was calculated as the slope on a load-displacement curve. For the press fit implants, alendronate treatment significantly increased bone ongrowth from 24% to 29% and significantly increased ultimate shear strength from 1.26 to 3.72 MPa. Also, the fraction of periprosthetic bone significantly increased from 10% to 18%. For implants surrounded by a gap, alendronate neither stimulated nor impaired implant fixation, bone ingrowth, or new bone formation in the gaps. Because early implant stability is an important predictor of longevity, systemic alendronate treatment could be an important clinical tool to positively influence the early stages of implant incorporation.
Collapse
Affiliation(s)
- Thomas B Jensen
- Orthopaedic Research Group, Department of Orthopaedics, Aarhus University Hospital, bygn 1a, 8000 Aarhus C, Denmark
| | | | | | | |
Collapse
|
54
|
Wermelin K, Tengvall P, Aspenberg P. Surface-bound bisphosphonates enhance screw fixation in rats--increasing effect up to 8 weeks after insertion. Acta Orthop 2007; 78:385-92. [PMID: 17611854 DOI: 10.1080/17453670710013979] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND A bisphosphonate coating improves screw fixation 2 weeks after implantation in cancellous bone. This study on rats examined further development of fixation over time for screws inserted in cancellous and cortical bone. METHODS SS screws were coated with a multiple layer of fibrinogen. Half of the screws were coated further with bisphosphonates, which were linked to the fibrinogen. The screws were inserted in cancellous and cortical bone in rats. The rats were killed after 5 h, 4 days, 1, 2, 4, 8, and 24 weeks, and fixation was evaluated by pullout test. RESULTS There was a gradual increase in pull-out force over time in both cancellous and cortical bone. The bisphosphonate coating improved fixation. Moreover, the difference between the bisphosphonate and control groups increased with time. The pull-out force was almost twice that of the controls for screws inserted in cancellous bone at 8 weeks. Energy uptake was increased more than 3-fold. DISCUSSION The energy uptake and pull-out force of a screw depends on the bone engaged with the threads. Thus, the presence of bisphosphonates increased the amount or quality of this bone by affecting the resorption/formation in a positive way. The increased effect of the bisphosphonates with time thus suggests that bisphosphonate is retained within the remodeling bone, with a positive effect on its gradual adaptation to the implant.
Collapse
Affiliation(s)
- Karin Wermelin
- Orthopedics Section, Department of Neuroscience and Locomotion, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
| | | | | |
Collapse
|
55
|
Greiner S, Kadow-Romacker A, Lübberstedt M, Schmidmaier G, Wildemann B. The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res A 2007; 80:769-75. [PMID: 17041912 DOI: 10.1002/jbm.a.30950] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Bisphosphonates such as zoledronic acid (ZOL) are used in diseases associated with osteoclast-mediated bone loss. However, their antiresorptive activity is partly due to their effect on osteoblasts. Local application might increase the therapeutical fence and their local efficiency and reduce systemic side effects. Aim of the study was to investigate the effect of ZOL on human osteoblasts like cells in vitro with special focus on the synthesis of factors mediating osteoclast differentiation (RANKL, OPG). ZOL was incorporated in an implant coating based on poly(D,L-lactide) (PDLLA) in different concentrations (10-150 microM). Control groups were treated with uncoated implants, PDLLA-coated implants, and ZOL pure substance in corresponding concentrations. After an experimental period of 144 h, primary human osteoblasts were stained with alamar blue and cell viability was measured. Procollagen I synthesis, osteoprotegerin (OPG) secretion, and soluble receptor activator of nuclear factor-kappaB ligand (sRANKL) were analyzed. Results showed that cell viability was not affected when treated with doses equivalent up to 100 microM ZOL-coated implants (ZOL-CI). Procollagen I synthesis was highest when treated with 50 microM ZOL-CI. OPG increased significantly in the 10 microM ZOL-CI group, whereas sRANKL decreased significantly with different concentrations of ZOL-CI. Higher concentrations or exposure to the pure substance showed a decrease in cell viability, collagen I, OPG, and sRANKL synthesis. In conclusion, exposure to specific concentrations of ZOL-CI showed a beneficial effect on osteoblast differentiation and protein synthesis without influencing their proliferation. Changes in sRANKL and OPG production may contribute to the inhibition of osteoclastic bone resorption. This local antiresorptive effect might be clinically useful in osseous implant integration and fracture healing.
Collapse
Affiliation(s)
- S Greiner
- Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Germany.
| | | | | | | | | |
Collapse
|
56
|
Moroni A, Faldini C, Hoang-Kim A, Pegreffi F, Giannini S. Alendronate improves screw fixation in osteoporotic bone. J Bone Joint Surg Am 2007; 89:96-101. [PMID: 17200316 DOI: 10.2106/jbjs.f.00484] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
BACKGROUND Animal studies have demonstrated the efficacy of the use of bisphosphonates to enhance screw fixation in bone. In this prospective, randomized study of pertrochanteric fractures treated with external fixation, we tested whether systemic administration of bisphosphonates would improve the fixation of hydroxyapatite-coated screws implanted in osteoporotic bone. METHODS Sixteen consecutive patients with a pertrochanteric fracture were selected. Inclusion criteria were female gender, an age of at least sixty-five years, and a bone mineral density T-score of less than -2.5 standard deviations. Exclusion criteria included bisphosphonate treatment during the two-year period prior to the fracture. Fractures were fixed with a pertrochanteric fixator and four hydroxyapatite-coated pins. Two pins were implanted in the femoral head (pin positions 1 and 2), and two were placed in the femoral diaphysis (pin positions 3 and 4). The patients were randomized either to therapy with alendronate for a three-month postoperative period (Group A) or to no therapy (Group B). The Group-A patients received an oral dose of 70 mg of alendronate per week. The fixators were removed after three months. RESULTS All of the fractures healed, and no loss of reduction, nonunion, or delayed union was observed. The combined mean extraction torque (and standard deviation) of the pins implanted at positions 1 and 2 (cancellous bone) was 2558 +/- 1103 N/mm in Group A and 1171 +/- 480 N/mm in Group B (p < 0.0005). The combined mean extraction torque of the pins implanted at positions 3 and 4 (cortical bone) was 4327 +/- 1720 N/mm in Group A and 4075 +/- 1022 N/mm in Group B. CONCLUSIONS These data show that weekly systemic administration of alendronate improves pin fixation in cancellous bone in elderly female patients with osteoporosis. We observed a twofold increase in extraction torque with the pins implanted in cancellous bone. These results support the use of alendronate in the treatment of osteoporotic pertrochanteric fractures to improve screw fixation in the femoral head.
Collapse
Affiliation(s)
- Antonio Moroni
- Rizzoli Orthopaedic Institute, University of Bologna, Via GC Pupilli 1, 40136 Bologna, Italy.
| | | | | | | | | |
Collapse
|
57
|
|
58
|
Moroni A, Hoang-Kim A, Lio V, Giannini S. Current augmentation fixation techniques for the osteoporotic patient. Scand J Surg 2006; 95:103-9. [PMID: 16821653 DOI: 10.1177/145749690609500205] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Osteoporosis is defined as the deterioration of microarchitecture and overall poor bone quality, which represents a risk of implant fixation failure when patients with osteoporosis are surgically treated. Fragility fractures in elderly patients, typically at the hip, spine and wrist, should be assessed by the orthopaedic surgeon prior to surgery in order to select the most appropriate technique necessary to overcome failures and other complications associated with reduced osteofixation. In this review, advanced methods of augmenting implant fixation in osteoporotic bone are described including polymethylmethacrylate (PMMA), bone grafts, calcium phosphate implants, calcium phosphate cements, calcium phosphate coatings, modified implants and pharmaceutical augmentation concepts. The indication for these techniques should be based on the quantitative assessment of the osteoporotic quality of bone evaluated by dual energy X-ray absorptiometry (DXA).
Collapse
Affiliation(s)
- A Moroni
- Rizzoli Orthopaedic Institute, University of Bologna, Bologna, Italy.
| | | | | | | |
Collapse
|
59
|
Kumar D, Kumar V, Little DG, Howman-Giles RB, Wong E, Ali SO. Evaluation of biodistribution by local versus systemic administration of 99mTc-labeled pamidronate. J Orthop Sci 2006; 11:512-20. [PMID: 17013741 DOI: 10.1007/s00776-006-1046-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2006] [Accepted: 05/24/2006] [Indexed: 11/29/2022]
Abstract
BACKGROUND There is an emerging interest in utilizing local and systemic administration of bisphosphonates in orthopedics. The primary objective of this study was to use (99m)Tc-pamidronate ((99m)Tc-PAM) as a tool and compare bone and tissue uptake by local versus systemic administration. METHODS (99m)Tc-PAM was administered intravenously (i.v.), subcutaneously (s.c.) and by direct application (d.a.) on a surgically exposed and fractured femur (d.a.#f). The animals were imaged at 2 h and 24 h after administration and then killed. Organs were harvested, and their radioactivity was estimated. Specific uptake in the right femur was compared between groups, as was systemic exposure to (99m)Tc PAM. RESULTS Bone uptake of (99m)Tc-PAM in the i.v. and s.c. groups was 2.2 +/- 0.15 and 0.65 +/- 0.07% ID/g, respectively, at the 2 h time point. Uptake by surgically exposed right femur (d.a) was 5.15 +/- 0.26% ID/g, 134% higher than the femoral uptake by the i.v. method (P < 0.05). In the presence of exposed bone when the femur was fractured (d.a.#f), the uptake was 7.89 +/- 0.46% ID/g, a further 50% increase (P < 0.05). The uptake of (99m)Tc-PAM increased after 24 h of application to 2.4 +/- 0.15, 1.53 +/- 0.09, 7.94 +/- 0.99, and 13.2 +/- 0.80% ID/g) for i.v., s.c., d.a., and d.a.#f methods, respectively. The increases in uptake for the d.a. methods were significantly higher than for the local methods at the 24-h time point (P < 0.05). Although renal uptake was comparable with the i.v. and s.c. methods (0.22 +/- 0.03 and 0.22 +/- 0.04% ID/g), it was significantly lower with the d.a. methods (0.05 +/- 0.07 and 0.16 +/- 0.07% ID/g) (P < 0.05). The corresponding urinary excretion was 55%, 45%, 36%, and 35% of the injected dose at 24 h. CONCLUSIONS The results indicate that the bone uptake of (99m)Tc-PAM was significantly higher (P = 0.001) and the kidney uptake significantly lower (P = 0.004) with the d.a. methods than with the i.v. or s.c. method. The findings indicate the need for further study into the potential of local administration of bisphosphonates in the presence of orthopedic indications.
Collapse
Affiliation(s)
- Divesh Kumar
- Department of Nuclear Medicine, University of Macquarie, Department of Biological Science, The Children's Hospital at Westmead and the Westmead Hospital, Westmead, Australia
| | | | | | | | | | | |
Collapse
|
60
|
Meunier A, Aspenberg P. Parecoxib impairs early metaphyseal bone healing in rats. Arch Orthop Trauma Surg 2006; 126:433-6. [PMID: 16810556 DOI: 10.1007/s00402-006-0160-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2005] [Indexed: 02/09/2023]
Abstract
INTRODUCTION Cox2 inhibitors decrease prostaglandin production and therefore influence bone healing especially in unstable long bone models. It is unclear to what extent implant fixation in stable metaphyseal bone is impaired. METHOD Male rats numbering 30 and female rats numbering 40 received a stainless steel screw in the metaphyseal bone of the proximal tibia. Half of the rats were treated with 6.4 mg/kg BW parecoxib by continuous release from a subcutaneous mini pump during 7 or 14 days. After treatment, the pull out force, stiffness, and pull out energy of the screw were measured. RESULTS No effect of parecoxib on the pull out force was found for male rats. In female rats the pull out force was decreased by 16% (P = 0.03) after 7 days treatment with parecoxib. This effect had disappeared after 14 days. CONCLUSION Adverse effects of parecoxib on the early phase healing of metaphyseal bone in female rats are small and were not detectable after 14 days. No effect was seen in male rats, possibly due to a faster metabolic elimination of the drug.
Collapse
Affiliation(s)
- Andreas Meunier
- Division of Orthopaedics and Sports Medicine, Department of Neuroscience and Locomotion, Faculty of Health Sciences, SE, 581 85 Linkoping, Sweden.
| | | |
Collapse
|
61
|
Goya JA, Paez HA, Mandalunis PM. Effect of Topical Administration of Monosodium Olpadronate on Experimental Periodontitis in Rats. J Periodontol 2006; 77:1-6. [PMID: 16579696 DOI: 10.1902/jop.2006.77.1.1] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND Periodontitis is characterized by gingival inflammation, periodontal pocket formation, and bacterial plaque that lead to alveolar bone destruction. Research studies have recently begun to evaluate the effect of antiresorptive agents using experimental models of periodontitis. Bisphosphonates are the most frequently tested antiresorptive agents; their main effect is inhibition of bone resorption. The aim of this study was to perform a histomorphometric evaluation of the preventive effect of monosodium olpadronate (OPD), an aminobisphosphonate, on experimental periodontitis (EP). METHODS Twenty male Wistar rats were used in this experiment. The animals were assigned to one of two groups: group I: EP; and group II: EP plus topical administration of OPD (EP + OPD). The contralateral side in both groups served as untreated controls (CI and CII), respectively. Mesio-distally oriented sections of each lower first molar were obtained for histomorphometric evaluation. RESULTS The treated group (EP + OPD) exhibited marked inhibition of bone loss; interradicular bone volume was significantly greater than that observed in the EP group. The height of the periodontal ligament in the interradicular alveolar bone, which served as an indirect measure of bone loss, was found to be significantly increased in the EP group as compared to the EP + OPD group. Osteoclasts in the OPD treated group were detached from the bone surface, were round in shape, and exhibited a loss of polarity and lack of ruffled borders. CONCLUSIONS The dose used herein was found to inhibit bone loss and to cause marked morphologic changes in osteoclasts. The drug effectively prevented bone loss caused by periodontitis.
Collapse
Affiliation(s)
- Juan A Goya
- Department of Histology and Embryology, Faculty of Dentistry, University of Buenos Aires, Buenos Aires, Argentina
| | | | | |
Collapse
|